NeuroOne shareholders elect director, ratify auditor, approve exec compensation vote every three years

NEUROONE MEDICAL TECHNOLOGIES Corp

Paul Buckman elected Class I director: 5,804,908 for, 1,363,109 withheld, 8,614,407 broker non-votes.
Ratification of Baker Tilly as independent auditor: 15,736,069 for, 36,991 against, 9,364 abstain.
Advisory approval of named executive officer compensation: 6,586,582 for, 330,506 against, 250,929 abstain.
Advisory vote on frequency of exec compensation votes: every three years selected (3,723,836 votes); board to implement that cycle.
60.89% of shares represented at meeting (15,782,424 of ~25.9M shares outstanding).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Election of Class I director Paul Buckman at the 2024-03-14 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-03-14

Exact text from the filing

Proposal 1—Election of Directors Class I Nominee Votes For Votes Withheld Broker Non-Votes Paul Buckman 5,804,908 1,363,109 8,614,407

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Ratification of appointment of Baker Tilly U.S., LLP as independent registered public accounting firm for fiscal year ending September 30, 2024 at the 2024-03-14 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-03-14

Exact text from the filing

Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Votes Abstain 15,736,069 36,991 9,364

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Advisory approval of frequency of future advisory votes on executive compensation: every three years (the frequency receiving the majority of votes cast) at the 2024-03-14 meeting.

Proposal: say on pay frequency
Outcome: passed
Meeting: 2024-03-14

Exact text from the filing

Proposal 4—Advisory Approval of the Frequency of an Advisory Vote on Named Executive Officers Compensation One Year Two Years Three Years Votes Abstain 3,060,695 144,245 3,723,836 239,241 For Proposal 4, “every three years” received the affirmative vote of the holders of a majority of the voting power of shares present

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Approval of the Company's named executive officers' compensation in an advisory vote at the 2024-03-14 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2024-03-14

Exact text from the filing

Proposal 3—Approval of the Company’s Named Executive Officers’ Compensation in an Advisory Vote Votes For Votes Against Votes Abstain 6,586,582 330,506 250,929

View on SEC.gov

560 shareholder votes filed in the last 30 days. Browse all shareholder votes →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-023083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.